Peptides for Fat Loss and Recomposition: A Beginner's Plain-English Guide

If you've spent any time in fitness corners of the internet lately, you've seen peptides pitched as a shortcut to a leaner body. Some of the excitement is earned. A lot of it is hype, broscience, and marketing dressed up as science. This guide is the calm, honest version — what peptides actually are, the main classes people discuss for fat loss and recomposition, what the evidence does and doesn't support, and the legal and safety realities you cannot afford to skip.

We're going to be straight with you the whole way: confident where the evidence is solid, honest where it's thin. No hype, no fear-mongering, no telling you what to inject.

Read this first. This is education, not medical advice, and it is not a recommendation to use any substance. Several peptides below are not FDA-approved, are sold as research chemicals, and/or are banned in sport. Talk to a licensed clinician about anything you're considering. We'll repeat the important caveats at the end.

What Is a Peptide, Actually?

A peptide is just a short chain of amino acids — the same building blocks that make up proteins, only smaller. Your body already makes thousands of them, and they act as signaling molecules: tiny messengers that tell cells to do things like release a hormone, modulate appetite, or kick off a repair process.

The peptides people use for fat loss and recomposition are synthetic versions of these messengers, designed to nudge a specific biological pathway. The fat-loss conversation almost always comes down to two pathways:

1. The incretin / GLP-1 pathway — peptides that act on appetite and metabolism.
2. The growth-hormone (GH) pathway — peptides that prompt your pituitary to release more of your own growth hormone.

Plus a third bucket of "supporting cast" peptides aimed at recovery rather than fat loss directly. Let's take them in order, because the strength of the evidence is wildly different across the three.

The Main Classes

1. GLP-1 Receptor Agonists (The Appetite Pathway)

This is the class with by far the strongest evidence — and the most genuine regulatory standing. GLP-1 peptides work mainly by suppressing appetite and slowing gastric emptying through signaling in the brain, which makes a calorie deficit dramatically easier to sustain.¹ The headline names are semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro, technically a dual GLP-1/GIP agonist).

The clinical data here is large and real. In the 2025 head-to-head SURMOUNT-5 trial, tirzepatide produced about 20.2% average body-weight reduction versus 13.7% for semaglutide over 72 weeks.²³ These are FDA-approved medications with extensive trials behind them — a completely different evidence tier from most of what gets called a "peptide" online.

The recomposition catch: GLP-1 weight loss reduces both fat and lean mass. Across the STEP (semaglutide) and SURMOUNT (tirzepatide) trials, fat makes up the majority of the loss — but lean tissue comes off too, and emerging real-world data suggests the lean-mass hit can be meaningful, possibly larger with tirzepatide in routine care.⁴⁵⁶ This is the reason the tracking matters: dramatic scale drops can hide unwanted muscle loss. Adequate protein and resistance training are the established levers for protecting lean mass during the cut.⁷⁸

2. Growth-Hormone Pathway Peptides (Secretagogues and GHRH Analogs)

This is where the conversation gets murkier and the evidence gets much thinner. These peptides — names like CJC-1295, ipamorelin, tesamorelin, and AOD-9604 — aim to increase your own growth-hormone output. GHRH analogs (like CJC-1295 and tesamorelin) mimic the hormone that tells your pituitary to release GH; secretagogues (like ipamorelin) stimulate that release through a different receptor. The theory is that more GH drives lipolysis (fat breakdown), especially visceral fat, while helping preserve lean mass.¹

Here's the honest evidence picture:

• The weight-loss evidence for GH-pathway peptides is far weaker than for GLP-1 drugs. They may modestly improve body composition, but they do not produce the dramatic scale reductions incretin drugs deliver.¹
• Tesamorelin is the one real outlier on credibility: it's the only FDA-approved GHRH analog, but its approval is narrow — reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy, not general fat loss.⁹¹⁰
• AOD-9604 (a fragment of GH marketed as a "fat-loss peptide") failed its Phase IIb primary endpoint, and clinical development was terminated back in 2007.¹ That's worth sitting with: a peptide still sold to consumers today flunked the trial that was supposed to prove it works.
• CJC-1295 + ipamorelin is not FDA-approved for any indication, and there are no established clinical guidelines supporting its use.¹¹¹²

So: real biology, plausible mechanism, but thin human outcome data and mostly non-approved status. Treat confident claims about these with heavy skepticism.

3. The "Supporting Cast" (Recovery Peptides)

You'll also see peptides like BPC-157 in the same conversations. These aren't fat-loss peptides — they're pitched for recovery, tissue repair, and gut health, on the theory that better recovery lets you train harder. The evidence is mostly preclinical (animal and lab studies), with limited rigorous human data,¹³ and the regulatory picture is unfriendly: the FDA classifies BPC-157 as a "Substance with Safety Concerns" (a Category 2 bulk drug substance), which prohibits licensed pharmacies from compounding it for human use.¹⁴ Interesting biology; not a fat-loss tool; not a settled safety story.

What to Track (So You're Not Just Guessing)

If you and a clinician decide a protocol makes sense, the worst thing you can do is judge it by the bathroom scale. Scale weight is mostly water day-to-day and hides the fat-vs-muscle story entirely.¹⁵ Track the small set of things that actually carry signal:

• Weight trend, not weight — daily morning weigh-ins, but judge only the 7-day average.¹⁵ A sane fat-loss pace is roughly 0.5–1% of bodyweight per week.
• Body-fat % and lean mass — via InBody, DEXA, or a quality smart scale, measured under identical conditions every time (same time of day, fasted, hydrated, rested). Watch the trend: body fat down, lean mass holding. This is the metric that catches GLP-1 muscle loss before it becomes a problem.
• Recovery and HRV — a wearable like Whoop shows whether the protocol-plus-deficit is a sustainable stress or quietly grinding you down. Watch your own baseline, not a universal number.
• Nutrition adherence — log calories and protein honestly (MyFitnessPal or similar). Without this, you literally can't tell whether a peptide did anything or whether you just ate less. Protein especially is what protects lean mass.⁷

The "started X" marker over these trend lines is the whole point — it's how you separate what the protocol changed from what your diet and training changed. Just remember you're an n=1 experiment with no control group: you can see that things changed, rarely prove the peptide caused it.

The Caveats Nobody Should Skip

This section isn't boilerplate. It's the part that keeps you safe.

Most of these are not approved, and many are research chemicals. With the exception of the FDA-approved GLP-1 medications and tesamorelin (for its narrow indication), the peptides above are largely unapproved, unauthorized developmental drug substances not legally intended for human consumption.¹¹¹² "Research use only" on a label is not a wink-and-nod — it reflects a genuine lack of the safety and efficacy data approval requires.

The supply chain is a real risk. The FDA has documented serious safety concerns with compounded products. As of mid-2025 it had received over 600 adverse-event reports for compounded semaglutide alone, and in September 2025 it issued more than 50 warning letters to GLP-1 compounders and sellers over false or misleading claims and manufacturing violations — including products made with bulk substance from sources that weren't FDA-registered.¹⁶¹⁷¹⁸ With grey-market peptides, you frequently don't actually know what's in the vial, the dose, or the purity.

Specific safety signals exist. The FDA has flagged compounded CJC-1295 for serious adverse events including increased heart rate and systemic vasodilatory reactions.¹¹ GH-pathway peptides can affect blood sugar and other systems. These are not consequence-free.

If you compete, assume it's banned. Growth hormone and GH secretagogues — including CJC-1295, ipamorelin, and tesamorelin — are on the WADA Prohibited List at all times (category S2). BPC-157 was temporarily prohibited by WADA in 2022.¹¹¹⁹ A banned-substance positive can end a competitive career.

Individual results vary, and interactions are real. Combining peptides changes side-effect risk, dosing, and monitoring needs — especially if you have a metabolic condition or take other medications.⁴ None of this is one-size-fits-all, and none of it replaces a conversation with someone who can see your full medical picture.

The Bottom Line

Peptides are a real and genuinely interesting area of metabolic science — not magic, not poison. The GLP-1 class has strong, FDA-backed evidence for weight loss (with a lean-mass cost worth managing). The growth-hormone class has plausible mechanisms but much thinner human evidence and mostly non-approved status. The recovery peptides are mostly preclinical and regulatorily fraught.

If you take one thing from this: a protocol is only as useful as your ability to tell whether it's working. Decide with a clinician, source responsibly and legally, respect the caveats — and then track the right metrics so you can see what actually changed, in plain language, instead of guessing with extra steps.

Sources

1. Superpower — Peptides for Fat Loss: What the Evidence Shows for Body Recomposition. https://superpower.com/guides/peptides-for-fat-loss
2. tctmd.com — Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5. https://www.tctmd.com/news/tirzepatide-tops-semaglutide-weight-loss-surmount-5
3. Applied Clinical Trials — Tirzepatide Demonstrates Superior Weight Loss to Semaglutide in 72-Week SURMOUNT-5 Trial. https://www.appliedclinicaltrialsonline.com/view/tirzepatide-weight-loss-semaglutide-surmount-trial
4. Potere Health — GLP-1 and Muscle Loss: Semaglutide, Tirzepatide & Lean Mass. https://www.poterehealthmd.com/post/glp1-muscle-loss-semaglutide-tirzepatide
5. Body composition changes during weight reduction with tirzepatide (SURMOUNT-1) — Diabetes, Obesity and Metabolism (Wiley). https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16275
6. Greater lean-body-mass decline with tirzepatide than semaglutide in routine care — medRxiv. https://www.medrxiv.org/content/10.64898/2026.04.11.26350687v1.full
7. Clinical Nutrition Center — Tirzepatide vs. Semaglutide: Lean Mass Preservation. https://www.clinicalnutritioncenter.com/research/tirzepatide-vs-semaglutide-lean-mass-preservation
8. Tirzepatide and muscle composition changes (SURPASS-3 MRI post-hoc analysis) — The Lancet Diabetes & Endocrinology. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00027-0/fulltext
9. Theratechnologies — FDA Approval for EGRIFTA WR (tesamorelin F8) for Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy. https://www.theratech.com/news-releases/news-release-details/theratechnologies-receives-fda-approval-egrifta-wrtm-tesamorelin/
10. PeptideWise — Tesamorelin (Egrifta): FDA-Approved GHRH Analog — Evidence Guide. https://www.getpeptidewise.com/peptides/tesamorelin/
11. BSCG — CJC-1295 Use in Sports and Military Rules Explained. https://www.bscg.org/blogs/single/cjc-1295-use-in-sports-and-military-rules-explained
12. Innerbody — CJC-1295 + Ipamorelin: Benefits, Safety & Buying Advice. https://www.innerbody.com/cjc-1295-and-ipamorelin
13. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11859134/
14. Holt Law — The Unregulated World of Peptides: What You Need to Know Before You Inject. https://djholtlaw.com/the-unregulated-world-of-peptides-what-you-need-to-know-before-you-inject/
15. Hume Health — Body Composition Analysis: What Your Scale Can't Tell You. https://humehealth.com/blogs/hume-blogs/body-composition-analysis-scale
16. MedShadow Foundation — FDA Drug Recalls and Warnings: Compounded Semaglutide and Tirzepatide. https://medshadow.org/drug-updates-recalls/fda-drug-recalls-and-warnings-recalls-for-compounded-semaglutide-and-tirzepatide-wegovy-facility-warning-letters/
17. Wilson Sonsini — FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers. https://www.wsgr.com/en/insights/fda-sends-warning-letters-to-more-than-50-glp-1-compounders-and-manufacturers.html
18. FDA — FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
19. Holt Law — Deep Dive: Regulatory Status of Popular Compounded Peptides. https://djholtlaw.com/deep-dive-regulatory-status-of-popular-compounded-peptides/

Medical Disclaimer

This article is for educational and informational purposes only and is not medical advice. It is not a recommendation to use, buy, or dose any peptide or medication, and it is not a substitute for diagnosis or treatment by a licensed healthcare provider. Always consult a qualified clinician before starting, stopping, or changing any peptide, medication, supplement, diet, or exercise program.

Many peptides described here are not approved by the FDA, are sold as research chemicals not intended for human consumption, and/or are prohibited in competitive sport under World Anti-Doping Agency (WADA) rules. Grey-market and compounded products carry documented risks of contamination, mislabeling, and inaccurate dosing. Regulatory status, legality, and safety vary by substance and jurisdiction and change over time — verify current rules for your situation.

Peptide OS is a personal data-tracking and education tool, not a medical device, pharmacy, or healthcare provider. It does not diagnose, treat, prescribe, or sell any substance, and it makes no claim that any peptide is safe or effective for you. Individual results vary. If you experience adverse symptoms, seek medical care promptly.